The efficacy of patient-tailored Intermittent Fasting (IF) regimens holds promising results to combat Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) due to excessive accumulation of fat in the liver, as per a study published in 'The European Journal of Gastroenterology & Hepatology'.

IF, also called as 'Eat-Stop-Eat' diet has emerged as a potential therapeutic option, offering advantages such as weight loss, improved insulin sensitivity, and reduced hepatic steatosis.

Mohamed T. Abuelazm et al. conducted a systematic review and network meta-analysis of randomized trials investigating the various IF regimens for managing MASLD. They thoroughly combed through databases including Web of Science, PubMed, EMBASE, SCOPUS and Cochrane Central Register of Controlled Trials up to April 10, 2023.

Their meta-analysis encompassed 8 randomized controlled trials involving 635 participants. Among the outcomes, the 5:2 diet stood out, significantly improving liver stiffness. Similarly, liver steatosis considerably improved time-restricted feeding, as indicated by the controlled attenuation parameter score.

However, the analysis did not reveal significant changes in various biomarkers and clinical parameters across all IF regimens, including AST (aspartate aminotransferase), GGT (gamma-glutamyl transpeptidase), lipid profiles, basal metabolic index, blood pressure, insulin resistance, abdominal obesity (waist circumference) and fasting blood sugar. It is worth noting that the alternate-day fasting exhibited positive outcomes in anthropometric measures, showing momentous improvements in lean body mass, abdominal obesity and overall weight loss.

While IF routines showcased diverse encouraging clinical outcomes in MASLD patients, the effects remain erratic.